SLC7A11 and Kaposi's sarcoma: Interestingly, xCT has also been identified as a fusion-entry receptor for KSHV [12, 13], which is upregulated within more advanced Kaposi's sarcoma (KS, another KSHV-related malignancy [14]) lesions containing a greater number of KSHV-infected cells [15].